Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04827446 · ClinicalTrials.gov registry record · NA
Lighting Intervention for Cancer-related Fatigue
A NA study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 139
- Enrollment target
NCT04827446: Completed NA study, sponsored by University of Michigan Rogel Cancer Center.
NCT04827446 is a NA study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 139 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04827446, a NA study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 139 participants
- Enrollment target
Study Summary
Fatigue is a major problem for cancer patients, and one that can persist long after treatment ends. Recent work has demonstrated that light therapy may mitigate or reduce fatigue levels in both cancer patients and cancer survivors. This protocol seeks to assess how lighting interventions distributed through a mobile app affect fatigue, sleep, and quality of life across three populations of cancer patients: breast cancer and prostate cancer, and patients who have undergone autologous hematopoietic stem cell transplant (HSCT). Participants will be randomized 1:1 to either the interventional SYNC app or to a control app.
Primary Outcome
The primary outcome was PROMIS® Fatigue 4a Short Form (SF) at the end of trial, compared between arms. As we did not have a PROMIS® 4-item Fatigue weekly measurement for week 0, we were unable to calculate a change from baseline through this measure alone. We assessed this outcome by looking at differences in fatigue between the intervention and control group at the final week (week 11), and the treatment effect on fatigue at week 11 while controlling (through generalized estimating equations) f
Interventions
- OTHER Wearable Sensor
- OTHER Blue-blocking glasses
- OTHER Clear glasses
- OTHER Full SYNC app
- OTHER "Dummy" SYNC app
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2023-03-09 |
| Phase | NA |
What the finished NCT04827446 record still lists
NCT04827446 is an interventional study that assigns participants to a tested intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 5 interventions - of which Wearable Sensor is the first listed.
NCT04827446 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04827446 about?
NCT04827446 is a clinical study titled "Lighting Intervention for Cancer-related Fatigue". Fatigue is a major problem for cancer patients, and one that can persist long after treatment ends. Recent work has demonstrated that light therapy may mitigate or reduce fatigue levels in both cancer patients and cancer survivors. This protocol seeks to assess how lighting interventions distributed...
What is the current status of trial NCT04827446?
This trial is currently completed. It is a NA study. The enrollment target is 139 participants. The study started on 2021-07-15. Estimated completion is 2023-03-09.
What interventions are being tested in trial NCT04827446?
The interventions under investigation include: Wearable Sensor (OTHER), Blue-blocking glasses (OTHER), Clear glasses (OTHER), Full SYNC app (OTHER), "Dummy" SYNC app (OTHER).
Who is sponsoring clinical trial NCT04827446?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04827446's enrollment target sits among peer trials
139 720th of 2000 higher than 1,281 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI